Oxford Biomedica transforms into a pure-play CDMO in cell and gene therapy
LONDON, UK: Oxford Biomedica, a leading cell and gene therapy CDMO, has announced a business update for the year ending 31 December 2023. The update highlights the Company’s progress in transforming its operations, expanding its client base, and enhancing its…